- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00299234
Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL
Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for Acute Lymphocytic Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this study is to assess the safety, tolerability and efficacy of atomoxetine as determined by the change in the ADHD-RS-IV Total score compared to placebo in the symptomatic treatment of patients diagnosed with Attention-Deficit/Hyperactivity Disorder (by DSM-IV ADHD-NOS criteria) occurring as a neuropsychological late-effect of chemotherapy used to treat Acute Lymphocytic Leukemia (ALL).
The secondary objectives are:
to assess the effect of once daily (AM) dosing of atomoxetine (1.8mg/kg) compared to placebo on ADHD symptoms as measured by:
- ADHD-RS Total score inclusive of subtypes for inattention, hyperactivity and combined subtypes.
- Clinical Global Impression-ADHD
- to evaluate the safety and tolerability of atomoxetine compared with placebo based on treatment-emergent adverse events (AEs), laboratory tests, vital signs, physical examinations, and ECGs.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Virginia
-
Norfolk, Virginia, United States, 23510
- Monarch Medical Research - Child and Adolescent Neurology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ages 6-18 years
- Must have successfully completed treatment for ALL and are currently 1-year "disease free" as judged by the investigators.
- Must meet DSM-IV criteria for "ADHD-NOS.( Attachment A) The attention deficit symptoms have been precipitated by chemotherapy-related neurological injury. Therefore, the DSM-IV category is ADHD-NOS.
- Must have an Investigator-completed ADHD-RS total and/or subscale score of ≥1.5 standard deviations above age/gender norm.
- Laboratory results, including chemistries, hematology, and urinalysis do not demonstrate clinically significant abnormalities.
- ECG demonstrates no clinically significant abnormalities
- Educational level and degree of understanding of the patient and their parents permit suitable communication between the investigators and study coordinators.
- Subjects and parents are judged to be reliable to keep appointments.
- Must be able to swallow tablets.
- Must have demonstrated compliance during their chemotherapy program.
- Must weigh > 20 kg.
Exclusion Criteria:
- Have relapsed or are having re-occurring symptoms/signs of ALL.
- Have had substantial exposure to radiation therapy (>2000: cGy) since high dose radiation treatment is associated with neurocognitive deficits or be "treatment resistant" pharmacologically.
- Past exposure to atomoxetine.
- ADHD symptoms or treatment prior to the diagnosis of ALL
- Documented bipolar disorder, psychosis, affective disorder.
- Female subjects who are pregnant or breastfeeding.
- Suicide risk.
- Seizure disorders (except history of febrile seizures).
- Histories of multiple drug allergies.
- Histories of alcohol or substance abuse.
- Prior or current medical conditions that, in the opinion of the investigators, could be exacerbated by atomoxetine.
- Sympathomimetic overactivity such as catecholamine secreting tumor.
- Use of MAOI medications.
- Have taken psychostimulants one week prior to randomization.
- Current or past history of hypertension.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
placebo
|
titration schedule: 0.5 to 1.5 mg/kg/day
|
Experimental: 1
atomoxetine
|
titration schedule: 0.5 to 1.5 mg/kg/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary outcome is the change in the ADHD-RS total score from baseline to completion of the study.
Time Frame: 5 weeks
|
5 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The secondary outcome is the difference in CGI categories by the treatment versus placebo group.
Time Frame: 5 weeks
|
5 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Donald W Lewis, MD, Monarch Medical Research
Publications and helpful links
General Publications
- Mulhern RK, Friedman AG, Stone PA. Acute lymphoblastic leukemia: long-term psychological outcome. Biomed Pharmacother. 1988;42(4):243-6.
- Schuler D, Bakos M, Borsi J, Gacsaly I, Kalmanchey R, Kardos G, Koos R, Nagy C, Revesz T, Somlo P, et al. Neuropsychologic and CT examinations in leukemic patients surviving 10 or more years. Med Pediatr Oncol. 1990;18(2):123-5. doi: 10.1002/mpo.2950180207.
- Goff JR, Anderson HR Jr, Cooper PF. Distractibility and memory deficits in long-term survivors of acute lymphoblastic leukemia. J Dev Behav Pediatr. 1980 Dec;1(4):158-63.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Disease
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Adrenergic Uptake Inhibitors
- Atomoxetine Hydrochloride
Other Study ID Numbers
- B4Z-MC-X040
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Hyperactivity Disorder
-
Cingulate TherapeuticsRecruitingPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Cingulate TherapeuticsPremier Research Group plcActive, not recruitingADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Children's National Research InstituteRecruitingADHD | Attention Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder | Attention Deficit Disorder | ADD | ADHD Predominantly Inattentive Type | ADHD - Combined Type | ADHD, Predominantly Hyperactive - Impulsive | Attention-Deficit Disorder in Adolescence | Attention-Deficit Hyperactivity...United States
-
Fondation LenvalCompletedAttention Deficit Disorder With Hyperactivity | Attention Deficit Disorder Without HyperactivityFrance
-
University Hospital Bispebjerg and FrederiksbergMental Health Services in the Capital Region, DenmarkRecruitingSleep Disturbance | Neurodevelopmental Disorders | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder | Attention-Deficit Hyperactivity Disorder, Unspecified Type | Attention-deficit Hyperactivity | Hyperkinetic Conduct DisorderDenmark
-
Corium, Inc.Worldwide Clinical Trials; Premier Research Group plc; Almac; Prometrika, LLCRecruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Corium, Inc.Premier Research Group plc; Almac; Prometrika, LLCActive, not recruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Massachusetts General HospitalShire Human Genetic Therapies, Inc.Active, not recruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Atatürk UniversityCompletedAttention-deficit/Hyperactivity DisorderTurkey
Clinical Trials on Atomoxetine
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...Recruiting
-
Eli Lilly and CompanyCompletedAttention Deficit Hyperactivity Disorder | Oppositional Defiant DisorderItaly
-
Eli Lilly and CompanyCompletedAttention Deficit Hyperactivity DisorderSpain, France, Austria, Germany, Belgium, Finland, Italy, Netherlands, Portugal, Sweden, Switzerland, United Kingdom
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA)TerminatedMethamphetamine Dependence | Methamphetamine AbuseUnited States
-
Brigham and Women's HospitalNot yet recruiting
-
Lindner Center of HOPEUniversity of CincinnatiCompleted
-
Poitiers University HospitalTerminated
-
NYU Langone HealthEli Lilly and CompanyCompletedAttention Deficit Hyperactivity Disorder
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedPhysiological Stress
-
Peking UniversityUnknownAttention Deficit Hyperactivity DisorderChina